Ardelyx Announces The Appointment Of Sue Hohenleitner As Chief Financial Officer, Effective November 4, 2025, To Drive Strategic Financial Growth
Ardelyx appoints Sue Hohenleitner as CFO, bringing 30+ years of financial and biotech leadership experience.
Breaking News
Oct 14, 2025
Simantini Singh Deo

Ardelyx, Inc., a biopharmaceutical company dedicated to discovering, developing, and commercializing innovative, first-in-class medicines to address significant unmet medical needs, has announced the appointment of Sue Hohenleitner as Chief Financial Officer (CFO), effective November 4, 2025. Sue Hohenleitner brings more than 30 years of extensive experience in corporate finance, strategic planning, investor relations, and operations, spanning multiple therapeutic areas and stages of development.
She is recognized for her ability to drive organizational transformation, strengthen financial performance, and support sustainable business growth. Most recently, she served as Vice President and Chief Financial Officer of Johnson & Johnson (J&J) Innovative Medicine North America, where she led financial strategies for a $36 billion commercial business.
Mike Raab, president and chief executive officer of Ardelyx, expressed his enthusiasm about the appointment, stating, “We are thrilled to welcome Sue to the Ardelyx leadership team. She is an accomplished financial leader with a strong record of executing growth strategies and driving operational excellence. Her forward-thinking approach and deep industry knowledge will play an important role as we continue to expand our commercial success and explore new opportunities for growth. Sue’s leadership and financial discipline will help accelerate our momentum and position Ardelyx for long-term success, while delivering value to patients, employees, and shareholders.”
Sharing her thoughts on joining the company, Sue Hohenleitner said, “I am very excited to join Ardelyx at such a pivotal stage in its journey. With two first-in-class medicines already making a difference for patients and strong plans for future expansion, I look forward to working with the team to shape strategic initiatives that will drive long-term growth and innovation. Together, we can continue to advance important new medicines and reach more patients who need our therapies.”
Before joining Ardelyx, Hohenleitner spent 28 years at Johnson & Johnson, where she led several finance organizations across supply chain, innovation, commercial operations, business development, investor relations, and financial planning and analysis. In her most recent role, she led multiple strategic initiatives that improved efficiency and effectiveness across the organization, providing increased funding for growth opportunities. She was also an instrumental partner in the successful execution of two major acquisitions that led to strong commercial launches.
Hohenleitner is a Certified Public Accountant in the Commonwealth of Pennsylvania and a Certified Management Accountant. She earned her Bachelor of Science in Accounting from La Salle University and a Master of Business Administration from Villanova University. Her accomplishments have been recognized by the industry, including being named one of the Top 25 CFOs in Biotech by Business & Investing.
She will assume her role as Chief Financial Officer on November 4, 2025, following the completion of Ardelyx’s third-quarter 2025 financial reporting. The company’s current Chief Financial and Operations Officer, Justin Renz, will continue in his role through the filing of Ardelyx’s Quarterly Report on Form 10-Q.